RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN PATIENTS WITH ABDOMINAL OBESITY AND ARTERIAL HYPERTENSION

Objective. The activity of renin-angiotensin-aldosterone system (RAAS) is increased in patients with ab-dominal obesity (AO). However, till present time it is unclear whether RAAS activation or hypertension (HTN) found in 50 % patients is the primary disorder.

Design and methods. We have studied plasma renin activity (PRA), plasma aldosterone concentration (PAC), their ratio PAC/PRA in patients with AO and related HTN and in subjects without AO.

Results. PRA was higher in patients with AO versus people without obesity (2,5 ± 0,2 and 1,7 ± 0,7 ng/ml/hr, p = 0,013), there was a tendency to the reduction of the ratio PAC/PRA in obese patients (14,6 ± 0,9 and 19,7 ± 3,3, p = 0,08). In the subgroup of patients with AO and HTN the PRA was higher, and the ratio PAC/PRA was lower than in obese patients without HTN (PRA: 3,3 ± 0,4 and 1,7±0,2 ng/ml/hr, p = 0,005; PAC/PRA: 11,4 ± 1,1 and 17,4 ± 1,4, p < 0,0001). PRA and systolic blood pressure positively correlated. In patients with morbid obesity (3 degree according to the WHO classiication) obesity may play a signiicant role in the increase of RAAS activity, especially in the absence of concomitant HTN. The ratio PAC/PRA in over weight patients with AO was higher than in patients with AO and body mass index ? 30,0 kg/m (17,2 ± 1,7 and 12,5 ± 1,0 kg/m, p = 0,04). PRA was higher only in patients with AO and co-existing hypertension (3,4 ± 0,7 and 1,1 ± 0,2 ng/ml/hr, p = 0,04).

Conclusions. RAAS activity is increased in patients with AO, also due to the co-existing HTN. However, in the absence of elevated blood pressure obesity per se may play a signiicant role in RAAS hyperactivity.

1. Shields M., Tremblay V.S., Janssen I. Abdominal obesity and cardiovascular disease risk factors within body mass index categories // Health Reports. — 2012. — Vol. 23, № 2. — Р. 7–15.

2. Goossens G.H., Jocken J.W.E., Blaak E.E. et al. Endocrine role of renin-angiotensin system in human adipose tissue and muscle. Effect of ?-adrenergic stimulation // Hypertension. — 2007. — Vol. 49, № 3. — Р. 542–547.

3. Scharma A.M. The obese patient with diabetes mellitus: from research targets to treatment options // Am. J. Med. — 2006. —Vol. 119, № 5, Suppl. 1. — Р. S17–S23.

4. Dzau V.J., Antman E.M., Black H.R. et al. The cardiovas-cular disease continuum validated: clinical evidence of improved patient outcomes: part I: pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease) // Circulation. — 2006. — Vol. 114, № 25. — Р. 2850–2870.

5. Hajer G.R., van Haeften T.W., Visseren F.L.J. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases // Eur. Heart J. — 2008. — Vol. 29, № 24. — Р. 2959–2971.

6. Samoch-Bonet D., Justo D., Rogowsky O., Saar N. et al. Platelet counts and platelet activation markers in obese patients // Hindawi Publishing Corporation Mediators of Inlammation. — 2008. — Vol. 2008. — Article ID 854153. — 6 р.

7. Cartier A. The inlammatory proile associated with abdominal obesity // CMR J. — 2010. — Vol. 3, № 2. — Р. 15–19.

8. Fuentes E., Fuentes F., Vilahur G. Mechanisms of chronic state of inlammation as mediators that link obese adipose tissue and metabolic syndrome // Hindawi Publishing Corporation Mediators of Inlammation. — 2013. — Vol. 2013. — Article ID 136584. — 11 р.

9. Batra A., Siegmund B. Role of visceral fat. // Dig. Dis. — 2012. — Vol. 30, № 1. — Р. 70–74.

10. Cassis L.A., Police S.B., Yiannikouris F., Thatcher S.E. Local adipose tissue renin-angiotensin system // Curr. Hypertens. — 2008. — Vol. 10, № 2. — Р. 93–98.

11. Kim S., Soltani-Bejnood M., Quinard-Boulange A. et al. The adipose tissue renin-angiotensin system modulates systemic markers of insulin sensitivity and activates the intrarenal renin-angiotensin system // J. Biomed. Biotech. — 2006. — Article ID 27012. — Р. 1–6.

12. Stiefel P., Vallejo-Vaz A.J., Garcia-Morillo S. et al. Role of the renin-angiotensin system and aldosterone on cardiometabolic syndrome // Int. J. Hypertens. — 2011. — Vol. 2011. — Article ID 685238. — 8 p.

13. O’Seaghdla C.M., Hwang S.J., Vasan R.S. et al. Correlation of renin angiotensin and aldosterone system activity with subcutaneous and visceral adiposity: the Framingham heart study // BMC Endocr. Disord. — 2012. — Vol. 12, № 3. — Р. 2–7.

14. Верткин А.Л., Скотников А.С. Артериальная гипертензия: перспективы современной фармакотерапии и значение высокоселективных блокаторов ангиотензиновых рецепторов // Рус. мед. журн. — 2009. — Том 17, № 18. — С. 1188–1194. / Vertkin A.L., Skotnikov A.S. Arterial hypertension: perspectives of the modern pharmacotherapy and the role of highly selective angiotensin receptor antagonists // Russian Medical Journal [Russkiy Meditsinskiy Zhurnal]. — 2009. — Vol. 17, № 18. — Р. 1188–1194 [Russian].

15. Engeli S., Negrel R., Sharma A.M. Physiology and pathophysiology of the adipose tissue renin-angiotensin system // Hypertension. — 2000. — Vol. 35, № 6. — Р. 1270–1277.

16. Lastra-Lastra G., Sowerst J.R., Restrepo-Erazo K. et al. Role of aldosterone and angiotensin II in insulin resistance: an update // Clin. Endocrinol. — 2009. — Vol. 71, № 1. — Р. 1–6.

17. Luther J.M., Brown N.J. The renin-angiotensin-aldosterone system and glucose homeostasis // Trends Pharmacol. Sci. — 2011. — Vol. 32, № 12. — Р. 734–739.

18. Асташкин В.И., Глезер М.Г. Ожирение и артериальная гипертония // Проблемы женского здоровья. — 2008. — T. 3, № 4. — С. 23–34. / Astashkin V.I., Glezer M.G. Obesity and hypertension // Problems of Women’s Health [Problemy Zhenskogo Zdorovia]. — 2008. — Vol. 3, № 4. — Р. 23–34 [Russian].

19. Bloomild G.L., Blocher C.R., Fakhry I.F. et al. Elevated intraabdominal pressure increases plasma renin activity and aldosterone levels // J. Trauma. — 1997. — Vol. 42, № 6. —Р. 997–1004.

20. Barbieri D.E., Ribeiro-Filho F.F., Ribeiro A.B. et al. Diuretic-induced potassium depletion and glucose intolerance are not related to hyperactivity of the renin-angiotensin-aldosterone system in hypertensive patients with the metabolic syndrome //J. Clin. Hypertens. (Greenwich). — 2009. — Vol. 11, № 10. —Р. 549–554.

21. Ferrario C.M., Strawn W. Role of the renin-angiotensin-aldosterone system and proinlammatory mediators in cardio-vascular disease // Am. J. Cardiol. — 2006. — Vol. 98, № 1. — Р. 121–128.

22. Благосклонная Я.В., Шляхто Е.В., Бабенко А.Ю. Эндокринология / Учебник для медицинских вузов. — СПб. : Спец-Лит, 2004. — 398 с.: ил. / Blagosklonnaya Ya.V., Shlyakhto E.V., Babenko A.Yu. Endocrinology / Textbook for medical university. — St Petersburg : SpetsLit, 2004. — 398 p.: ill. [Russian].

23. Nicklas B.J., Cesari M., Pennix D.W.J.H. et al. Abdominal obesity is an independent risk factor for chronic heart failure in older people // J. Am. Geriatr. Soc. — 2006. — Vol. 54, № 3. — Р. 413–420.

24. Ammar K.A., Redield M.M., Mahoney D.W., Johnson M., Jacobsen S.J., Rodeheffer R. Central obesity association with left ventricular dysfunction and mortality in the community // Am. Heart. J. — 2008. — Vol. 156, № 5. — Р. 975–981.

25. Ali T., Hochfeld W.E., Myburgh R., Pepper M.S. Adipocyte and adipogenesis // Eur. J. Cell Biol. — 2013. — Vol. 92, № 6–7. — Р. 229–236.

26. Mankowska A., Sypniewska G. New adipokines linked to obesity and obesity-related diseases // J. Int. Fed. Clin. Chem. Lab. Med. — 2006. — Vol. 17, № 4. — [Electronic resource]. — URL: w.ifcc.org/ifcc-communications-publications-division-(cpd)/ifcc-publications/ejifcc-(journal)/e-journal-volumes/ejifcc-2006-vol-17/vol-17-n°-4/new-adipokines-linked-to-obesity-and-obesity-related-diseases/

27. Беляева О.Д., Баженова Е.А., Березина А.В. и др. Уровень лептина, распределение генотипов и встречаемость аллелей А19G полиморфизма гена лептина у пациентов с абдоминальным ожирением // Артериальная гипертензия. — 2009. — Т. 15, № 4. — С. 440–444. / Belyaeva O.D., Bazhenova E.A., Berezina A.V. et al. Leptin levels and A19G leptin gene polymorphisms in patients with abdominal obesity // Arterial Hypertension [Arterialnaya Gipertenziya]. — 2009. — Vol. 15, № 4. — P. 440–444 [Russian].

28. Abramov D., Carson P.E. The role of angiotensin receptor blockers in reducing the risk of cardiovascular disease // J. Renin Angiotensin Aldosterone System. — 2012. — Vol. 13, № 3. — Р. 317–327.

29. Ma T.K., Kam K.K., Yan B.P., Lam Y.Y. Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status // Br. J. Pharmacol. — 2010. — Vol. 160, № 6. — Р. 1273–1292.